Egalet forms new specialist pharmaceutical sales force to market SPRIX & OXAYDO.
M2 EQUITYBITES-June 24, 2015-Egalet forms new specialist pharmaceutical sales force to market SPRIX & OXAYDO
(C)2015 M2 COMMUNICATIONS http://www.m2.com
Pharmaceutical company Egalet Corporation (NasdaqGM:EGLT) reported on Tuesday the establishment of its specialty sales force to support the promotion of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only -CII.
The company said the sales force will focus on the top prescribing healthcare providers who prescribe pain medication. The sales representatives will begin making office visits to educate healthcare providers on SPRIX following the completion of sales training. The promotion of OXAYDO will begin by the end of the third quarter.
For eligible patients prescribed SPRIX, there is an automatic co-pay savings programme, added the company.
According to the company, OXAYDO tablets for oral use only -CII is the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting, for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug (NSAID), is indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jun 24, 2015|
|Previous Article:||Horizon Pharma anticipates additionsl US patent covering RAVICTI (Glycerol Phenylbutyrate) Oral Liquid for use as nitrogen-binding agent.|
|Next Article:||COPT prices offering of USD300m senior notes due 2025.|